1. Home
  2. NN vs WVE Comparison

NN vs WVE Comparison

Compare NN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextNav Inc.

NN

NextNav Inc.

HOLD

Current Price

$18.21

Market Cap

2.3B

Sector

Industrials

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$11.94

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NN
WVE
Founded
2007
2012
Country
United States
Singapore
Employees
96
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.4B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NN
WVE
Price
$18.21
$11.94
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
$31.47
AVG Volume (30 Days)
1.1M
2.1M
Earning Date
03-17-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$119.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$10.65
$5.28
52 Week High
$19.91
$21.73

Technical Indicators

Market Signals
Indicator
NN
WVE
Relative Strength Index (RSI) 64.50 37.81
Support Level $15.46 $6.61
Resistance Level N/A $14.50
Average True Range (ATR) 1.21 0.79
MACD 0.06 -0.17
Stochastic Oscillator 60.51 3.17

Price Performance

Historical Comparison
NN
WVE

About NN NextNav Inc.

NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: